BiotechTube

V920

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus

Conditions

Ebola Virus

Trial Timeline

Oct 13, 2014 → Aug 25, 2015

NCT ID
NCT02269423

About V920

V920 is a phase 1 stage product being developed by Merck for Ebola Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT02269423. Target conditions include Ebola Virus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT02269423Phase 1Completed
NCT02280408Phase 1Completed

Competing Products

20 competing products in Ebola Virus

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
52
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)MerckPhase 1/2
41
V920 VaccineMerckPhase 1
33
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)MerckPhase 2
52
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
85
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
52
V920MerckPhase 1
33
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
77
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
85
GS-5734Gilead SciencesPhase 2
51
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
22
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
51
AVI-7537United TherapeuticsPhase 1
30
Placebo + AVI-6002United TherapeuticsPhase 1
30
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
74
CMX001Jazz PharmaceuticalsPhase 2
49
BrincidofovirJazz PharmaceuticalsPhase 2
49
cAd3-Marburg + cAd3-EBO-SICON plc.Phase 1
30
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
28
TKM-100802 for Injection + PlaceboArbutus BiopharmaPhase 1
28

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85